New radioactive therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07441837
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a radioactive drug called terbium-161 PSMA in 60 men with metastatic prostate cancer that has worsened after standard treatments. The drug is designed to seek out and destroy cancer cells. Participants will receive three cycles of the drug, and researchers will monitor tumor response, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Terbium-161 PSMA I&T (a radioactive drug that targets prostate cancer cells)
What this could lead to
If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drug may not shrink tumors or improve survival, and it can cause side effects like bone marrow suppression or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anadolu Sağlık Merkezi
Istanbul, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ankara University Medical School Dept of Nuclear Medicine
Ankara, 06590, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Bilkent City Hospital
Ankara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sisli Hospital
Istanbul, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact